The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

2021-04-01T15:24:10-05:00April 1st, 2021|

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after [...]

Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial ahead of Planned Commercial Test

2021-04-01T15:20:10-05:00April 1st, 2021|

Delfi Diagnostics, Inc., a pioneering developer of next generation high performance, affordable liquid biopsy tests for early cancer detection, announced the start of enrollment for a nationwide prospective study and plans to commercialize an initial test in lung cancer before expanding into other cancer types. The Delfi lung cancer screening test, which combines advanced [...]

SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform

2021-04-01T15:16:55-05:00April 1st, 2021|

SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial intelligence and machine learning, and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have [...]

Genome Medical Expands Board of Directors and Leadership Team as Demand for Genomics Telehealth Services Grows

2021-04-01T15:13:13-05:00April 1st, 2021|

 Genome Medical, a digital health company bringing genetics and genomics into everyday care, today announced the appointment of Russell Glass, CEO of on-demand mental health company Ginger, to its Board of Directors as an independent director. In addition, to help guide the company's ongoing rapid growth, Genome Medical has appointed two key leaders to its [...]

Go to Top